A number of other analysts also recently weighed in on the stock. J P Morgan Chase & Co set a €62.00 ($73.81) price target on shares of MorphoSys AG and gave the stock a neutral rating in a report on Friday, August 4th. Berenberg Bank set a €68.00 ($80.95) price target on shares of MorphoSys AG and gave the stock a buy rating in a report on Wednesday, August 16th. Deutsche Bank AG set a €90.00 ($107.14) price target on shares of MorphoSys AG and gave the stock a buy rating in a report on Thursday, September 7th. Independent Research GmbH set a €77.00 ($91.67) price target on shares of MorphoSys AG and gave the stock a buy rating in a report on Thursday, September 7th. Finally, Goldman Sachs Group, Inc. (The) set a €55.00 ($65.48) price target on shares of MorphoSys AG and gave the stock a neutral rating in a report on Monday, July 24th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and an average price target of €70.38 ($83.78).
MorphoSys AG (ETR MOR) opened at 70.869 on Thursday. The company’s market cap is €2.05 billion. The stock has a 50 day moving average of €60.74 and a 200-day moving average of €59.75. MorphoSys AG has a 1-year low of €35.72 and a 1-year high of €71.91.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://transcriptdaily.com/2017/09/24/commerzbank-ag-reiterates-76-00-price-target-for-morphosys-ag-mor.html.
MorphoSys AG Company Profile
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with MarketBeat.com's FREE daily email newsletter.